{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:23Z","timestamp":1792693283214,"version":"4.5.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Global Infect Dis"],"published-print":{"date-parts":[[2010]]},"DOI":"10.4103\/0974-777x.62886","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T01:59:47Z","timestamp":1273111187000},"page":"159","source":"Crossref","is-referenced-by-count":202,"title":["Liposomal amphotericin B and leishmaniasis: Dose and response"],"prefix":"10.4103","volume":"2","author":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0974-777X.62886-1","unstructured":"World Health Organization. Leishmaniasis disease burden. Available from: http:\/\/www.who.int\/leishmaniasis\/burden\/en\/. Accessed on 2.9.2009"},{"key":"key-10.4103\/0974-777X.62886-2","unstructured":"Pearson RD, Jeronimo SMB, de Queiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 1999. p. 797-813."},{"key":"key-10.4103\/0974-777X.62886-3","first-page":"655","volume-title":"Risk factors for kala-azar in Bangladesh","author":"Bern","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-4","first-page":"341","volume-title":"Ten years of kala-azar in west Bengal, part I: did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?","author":"Addy","year":"1992","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0974-777X.62886-5","unstructured":"Minutes of the Meeting of the Expert Committee for the Treatment of Kala-azar in India. 2000."},{"key":"key-10.4103\/0974-777X.62886-6","first-page":"5","volume-title":"Childhood Mediterranean visceral leishmaniasis","author":"Cascio","year":"2003","journal-title":"Infez Med"},{"key":"key-10.4103\/0974-777X.62886-7","first-page":"133","volume-title":"Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)","author":"Russo","year":"1996","journal-title":"J Infect"},{"key":"key-10.4103\/0974-777X.62886-8","first-page":"75","volume-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial","author":"Davidson","year":"1994","journal-title":"Q J Med"},{"key":"key-10.4103\/0974-777X.62886-9","first-page":"66","volume-title":"Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of five clinical cases","author":"Montana","year":"2004","journal-title":"Pathol Biol"},{"key":"key-10.4103\/0974-777X.62886-10","first-page":"1","volume-title":"Report of a WHO Expert Committee","author":"The","year":"1984","journal-title":"World Health Organ Tech Rep Ser"},{"key":"key-10.4103\/0974-777X.62886-11","first-page":"1","volume-title":"Report of a WHO Expert Committee.World Health Organ","author":"Control","year":"1990","journal-title":"Tech Rep Ser"},{"key":"key-10.4103\/0974-777X.62886-12","first-page":"895","volume-title":"Comparison of regimens of treatment with sodium stibogluconate in Kala-azar","author":"Thakur","year":"1984","journal-title":"Br Med J"},{"key":"key-10.4103\/0974-777X.62886-13","first-page":"1557","volume-title":"Rationalization of regimens of treatment of Kala-azar with sodium stibogluconate in India: a randomized study","author":"Thakur","year":"1988","journal-title":"Br Med J"},{"key":"key-10.4103\/0974-777X.62886-14","first-page":"1117","volume-title":"Response to interferon-gamma plus pentavalent antimony in Indian visceral Leishmaniasis","author":"Sundar","year":"1997","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-15","first-page":"314","volume-title":"Changing response to diamidine compounds in cases of Kala-azar unresponsive to antimonials","author":"Jha","year":"1991","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/0974-777X.62886-16","first-page":"252","volume-title":"Pentamidine induced diabetes mellitus","author":"Jha","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62886-17","first-page":"926","volume-title":"Amphotericin B for second line treatment of Indian Kala-azar","author":"Mishra","year":"1991","journal-title":"Lancet"},{"key":"key-10.4103\/0974-777X.62886-18","first-page":"1739","volume-title":"Oral miltefosine for Indian visceral leishmaniasis","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62886-19","first-page":"1005","volume-title":"A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in India","author":"Jha","year":"2005","journal-title":"Amer J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62886-20","doi-asserted-by":"crossref","unstructured":"Wassuna M, Felton J, Sabin A, Horton J. A phase II dose-rising study of sitamaquin for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73:871-6","DOI":"10.4269\/ajtmh.2005.73.871"},{"key":"key-10.4103\/0974-777X.62886-21","first-page":"2571","volume-title":"Injectable paromomycin for visceral leishmaniasis in India","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0974-777X.62886-22","first-page":"2821","volume-title":"Treatment of visceral leishmaniasis","author":"Sundar","year":"2005","journal-title":"Expert Opin Pharmaco Ther"},{"key":"key-10.4103\/0974-777X.62886-23","first-page":"828","volume-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents and Chemother"},{"key":"key-10.4103\/0974-777X.62886-24","first-page":"179","volume-title":"Effect of tissue penetration on AmBisome efficacy","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"key-10.4103\/0974-777X.62886-25","first-page":"713","volume-title":"Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits","author":"Lee","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0974-777X.62886-26","first-page":"3487","volume-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi:maximum tolerated dose study","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0974-777X.62886-27","first-page":"319","volume-title":"Comparison of three treatment regimens with liposomal amphotericinB (AmBisome) for visceral leishmaniasis in India: a randomized dose finding study","author":"Thakur","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62886-28","first-page":"67","volume-title":"A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study","author":"Thakur","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0974-777X.62886-29","first-page":"419","volume-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"key-10.4103\/0974-777X.62886-30","first-page":"143","volume-title":"Lowdose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study","author":"Sundar","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62886-31","first-page":"800","volume-title":"Singledose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study","author":"Sundar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-32","first-page":"377","volume-title":"AmphotericinB treatment for Indian visceral leishmaniasis: conventionalversus lipid formulations","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-33","unstructured":"Report of a WHO informal Consultation on \u2032\u2032Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis\u2032\u2032. Rome, Italy, 16 April 2005 Available from: http:\/\/www.who.int\/neglected_diseases\/resources\/AmBisome-Report.pdf."},{"key":"key-10.4103\/0974-777X.62886-34","first-page":"188","volume-title":"Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions","author":"Seaman","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-35","first-page":"25","volume-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","author":"Berman","year":"1998","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0974-777X.62886-36","first-page":"938","volume-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-37","first-page":"271","volume-title":"Treatment of visceral leishmaniasis in children with liposomal amphotericin B","author":"di","year":"1997","journal-title":"J Pediatr"},{"key":"key-10.4103\/0974-777X.62886-38","first-page":"560","volume-title":"Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis","author":"Syriopoulou","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-39","first-page":"26","volume-title":"Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?","author":"Kafetzis","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0974-777X.62886-40","first-page":"42","volume-title":"US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-41","first-page":"625","volume-title":"Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus","author":"Torre-Cisneros","year":"1993","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-42","first-page":"1018","volume-title":"Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds","author":"Lazanas","year":"1993","journal-title":"AIDS"},{"key":"key-10.4103\/0974-777X.62886-43","first-page":"711","volume-title":"Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus","author":"Laguna","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-44","first-page":"837","volume-title":"Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","author":"Molina","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0974-777X.62886-45","first-page":"2946","volume-title":"Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy","author":"Berenguer","year":"2000","journal-title":"AIDS"},{"key":"key-10.4103\/0974-777X.62886-46","first-page":"540","volume-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","author":"L\u03c3pez-V\u03b9lez","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0974-777X.62886-47","first-page":"135","volume-title":"Treatment of leishmaniasis in HIV-positive patients","author":"Laguna","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"key-10.4103\/0974-777X.62886-48","doi-asserted-by":"crossref","unstructured":"Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990;84:221-5.7.","DOI":"10.1016\/0035-9203(90)90263-E"},{"key":"key-10.4103\/0974-777X.62886-49","first-page":"615","volume-title":"Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycin)-antimonial combinations, a pilot study in Bihar, India","author":"Thakur","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0974-777X.62886-50","first-page":"715","volume-title":"Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone","author":"Seaman","year":"1993","journal-title":"J Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-51","first-page":"1000","volume-title":"New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0974-777X.62886-52","first-page":"88","volume-title":"Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India","author":"Olliaro","year":"2009","journal-title":"Trop Med Int Health"}],"container-title":["Journal of Global Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:51:13Z","timestamp":1786632673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0974-777X.62886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"alternative-id":["62886"],"URL":"https:\/\/doi.org\/10.4103\/0974-777x.62886","relation":{},"ISSN":["0974-777X"],"issn-type":[{"value":"0974-777X","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}